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Abstract
Alzheimer's disease (AD) is a devastating and progressive neurodegenerative disease
for which there is no cure. Mild cognitive impairment (MCI) is considered a prodromal
stage of the disease. Molecular imaging with positron emission tomography (PET)
allows for the in vivo visualisation and tracking of pathophysiological changes in AD
and MCI. PET is a very promising methodology for differential diagnosis and novel
targets of PET imaging might also serve as biomarkers for disease-modifying thera-
peutic interventions. This review provides an overview of the current status and
applications of in vivo molecular imaging of AD pathology, specifically amyloid, tau,
and microglial activation. PET imaging studies were included and evaluated as poten-
tial biomarkers and for monitoring disease progression. Although the majority of
radiotracers showed the ability to discriminate AD and MCI patients from healthy
controls, they had various limitations that prevent the recommendation of a single
technique or tracer as an optimal biomarker. Newer research examining amyloid, tau,
and microglial PET imaging in combination suggest an alternative approach in study-
ing the disease process.
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1 | INTRODUCTION
Alzheimer's disease (AD) is the most common cause of dementia
worldwide. It is estimated that by 2050, 1 in 85 people worldwide will
develop AD (Brookmeyer, Johnson, Ziegler-Graham, & Arrighi, 2007).
The prodromal phase of AD, defined as mild cognitive impairment
(MCI), is characterised by declines in performance of one or more cog-
nitive domains with the preservation of functional independence
(Petersen, 2004). Central nervous system (CNS) degeneration and dis-
ease neuropathology predates AD and MCI. This is particularly true in
presymptomatic carriers of apolipoprotein E (APOE) ε4 (Reiman et al.,
2009), which is the leading genetic risk factor for AD (Liu et al., 2014).
The hallmark neuropathological substrates for AD and MCI are
β-amyloid (Aβ) plaques and intracellular tau neurofibrillary tangles
(NFTs). One major theory, the ‘amyloid cascade hypothesis’, suggests
that the overproduction combined with dysfunctional clearance of Aβ
is the fundamental event that initiates AD pathogenesis (Hardy &
Selkoe, 2002). However, several lines of evidence challenge this
assumption. For example, approximately 30% of healthy elderly indi-
viduals have significant levels of Aβ deposition without apparent clini-
cal symptoms (Rowe et al., 2010). In AD, histopathological evidence
suggests that Aβ levels are a poor predictor of severity of cognitive
impairment (Giannakopoulos et al., 2003) and anti-amyloid interven-
tions have demonstrated limited efficacy in clinical trials (Karran &
Hardy, 2014). Presence and extent of hyperphosphorylated tau-based
NFT pathology is positively associated with disease duration and
severity of cognitive symptoms (Gómez-Isla et al., 1997). In addition
to the more traditional markers of AD pathology, the existence of
neuroinflammation in AD is currently well established. Whilst the ini-
tial inflammatory response aims to ameliorate neuronal injury, abnor-
mally prolonged microglial activation can have detrimental effects and
potentially serve to exacerbate neurodegeneration (Fakhoury, 2018).
Positron emission tomography (PET) is a neuroimaging tool
designed to measure in vivo molecular processes in the brain. PET
radioligands bind a target, such as a receptor, a transporter, or an
enzyme. Degree of tracer binding or uptake is used to quantify neuro-
pathology. This technology may be particularly useful for diagnostic
purposes, treatment planning, and to assess disease progression in
neurological illnesses (Politis & Piccini, 2012). PET biomarkers that
have been recommended to improve diagnostic accuracy for AD and
MCI include decreased cerebral metabolism on [18F]fludeoxyglucose
(FDG) PET and increased Aβ deposition on amyloid PET (Albert et al.,
2011; McKhann et al., 2011). Rates of cerebral metabolism do not
explicitly elucidate potential disease-causing neuropathology, but
more likely highlight the degree of neuronal activity (Marcus, Mena, &
Subramaniam, 2014). Characteristic region-based patterns of brain
hypometabolism have been established within a range of different
dementia aetiologies (Kato, Inui, Nakamura, & Ito, 2016; Minoshima,
Frey, Koeppe, Foster, & Kuhl, 1995; Moonga et al., 2017; Mosconi
et al., 2008; Nestor, Caine, Fryer, Clarke, & Hodges, 2003). PET
tracers that measure Aβ burden, tau aggregation, and neu-
roinflammation provide remarkable insight directly into the processes
underlying the pathophysiology of AD and MCI; however, the latter
two have not yet been suggested for use in clinical practice. This
review describes the recent developments and current applications of
PET imaging of amyloid, tau, and neuroinflammation in AD and MCI.
Abnormalities on magnetic resonance imaging (MRI) have also been
used as clinically relevant imaging markers for AD and MCI (Chandra,
Dervenoulas, Politis, & Alzheimer's Disease Neuroimaging Initiative,
2018); however, this is not within the scope of the current work.
2 | AMYLOID STUDIES
2.1 | 11C-labelled amyloid tracers
Klunk et al. discovered what would become the most heavily researched
amyloid PET radiotracer, 11C-labelled Pittsburgh compound B ([11C]PiB;
Table 1) (Klunk et al., 2004). In their seminal study, it was shown that this
benzothiazole-based radioligand was capable of discriminating between
patients with a diagnosis of extremely mild AD and healthy controls.
Areas such as frontal and temporoparietal cortex, which are particularly
susceptible to Aβ pathology, demonstrated increased [11C]PiB retention
in AD. These findings have been replicated, and moreover, recent findings
highlight intermediate regional binding of [11C]PiB in MCI when com-
pared to healthy controls and AD patients (Rowe et al., 2010; Villemagne
et al., 2013). PiB PET has demonstrated the ability to bind to cored and
neuritic Aβ plaques, and also diffuse ones (Ikonomovic et al., 2008).
Amyloid load as measured by [11C]PiB in vivo has also been asso-
ciated with other markers of AD including brain atrophy (Archer et al.,
2006), medial temporal hypometabolism on [18F]FDG PET, impaired
memory performance (Frings, Spehl, Weber, Hüll, & Meyer, 2013),
and Aβ pathology from post-mortem brain tissue (Driscoll et al.,
2012). Regarding disease progression, cortical [11C]PiB uptake in fron-
tal, temporal, and cingulate areas was found to be predictive of phe-
noconversion from MCI to AD (Brück et al., 2013). It is important to
concede that MCI patients display a bimodal distribution for amyloid
uptake where amyloid load is significantly elevated in a proportion of
some MCI patients but not others (Hatashita et al., 2014; Nordberg
et al., 2013) (Table 2). Because of this, mean levels of amyloid accu-
mulation may not be the most reliable discriminator in MCI. In line,
MCI patients with elevated binding of [11C]PiB were more likely to
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TABLE 1 Studies examining in vivo regional brain uptake using amyloid tracers in AD and MCI
Study Amyloid tracer Study population Main findings
Klunk et al. (2004) [11C]PiB 16 AD patients,
9 healthy controls
Compared to healthy controls, AD patients showed increased tracer
retention in all four lobes of the cortex, in addition to the striatum.
Regions including pons, subcortical white matter, and the cerebellum,
which are typically unaffected by amyloid depositions showed no
such differences. Regional amyloid retention was negatively
associated with glucose metabolism as measured by FDG PET.
Rowe et al. (2010) [11C]PiB 53 AD patients,
57 MCI patients,
177 healthy
controls
Relative to healthy controls, AD andMCI patients demonstrated
increased PiB binding in the cortex. This was higher for AD patients
compared to those with MCI. Regions that showed notable tracer
uptake for patients included the precuneus, posterior cingulate,
orbitofrontal, lateral temporal cortex, and striatum.
Brück et al. (2013) [11C]PiB 29 MCI patients Elevated amyloid retention in areas within the cingulate and frontal
and temporal cortex was predictive of conversion fromMCI to AD.
Wolk et al. (2012) [11C]PiB
[18F]florbetapir
12 AD patients,
14 cognitively
normal subjects
Both amyloid tracers showed that AD patients had higher binding in
areas that included the anterior cingulate, posterior cingulate,
precuneus, frontal, parietal, and lateral temporal cortex compared
to cognitively normal subjects. There was also region-based
positive correlations between the two ligands.
Camus et al. (2012) [18F]florbetapir 13 AD patients,
12 MCI patients,
21 healthy controls
In AD, increased tracer retention was demonstrated for all 4 lobes
of the cortex, in addition to the precuneus and cingulate cortex
when compared to healthy controls. MCI patients demonstrated a
similar pattern, but primarily in the posterior cingulate cortex.
Johnson et al. (2013) [18F]florbetapir 45 AD patients,
60 MCI patients,
79 healthy controls
Amyloid retention was higher in frontal, temporal, and parietal
cortical areas, in addition to the cingulate and precuneus for AD
patients compared to healthy controls. Patients with MCI showed
similar but intermediate effects.
Namiki et al. (2015) [18F]florbetapir 15 AD patients,
15 MCI patients,
18 cognitively
normal subjects
AD patients showed increased [18F]florbetapir binding in the frontal
cortex, temporal cortex, parietal cortex, cingulate cortex, and
precuneus compared to cognitively normal subjects. No such
differences were found for MCI patients relative to controls.
Higher binding in the temporal, parietal, and cingulate cortex was
found in AD versus MCI.
Wong et al. (2010) [18F]florbetapir 16 AD patients,
16 healthy
controls
Compared to healthy controls, AD patients displayed greater tracer
retention in frontal, temporal, occipital, parietal, cingulate cortices,
in addition to the precuneus.
Barthel et al. (2011) [18F]florbetaben 81 AD patients,
69 healthy
controls
Cortical uptake in all regions including temporal, parietal, frontal,
occipital, and both posterior and anterior cingulate cortex was
higher in AD patients when compared to healthy controls. The
posterior cingulate cortex had the best ability to discriminate
between the two groups. Regional uptake values had a sensitivity
of 85% and a specificity of 91% and were inversely related to
global cognitive and memory performance.
Nelissen et al. (2009) [18F]
flutemetamol
Eight AD patients,
eight healthy
controls
Regions that showed increased tracer retention for AD patients
included the anterior cingulate, frontal cortex, lateral temporal
cortex, parietal cortex, posterior cingulate, sensorimotor cortex,
and striatum relative to healthy controls.
Rowe et al. (2008) [18F]florbetaben 15 AD patients,
15 healthy
controls
Regional binding was observed in cortical areas for AD patients,
moreso in the frontal cortex, precuneus and posterior cingulate
than in parietal and lateral temporal areas compared to controls.
Limited binding was observed in occipital, sensorimotor, and
mesial temporal areas.
Villemagne et al.
(2011)
[18F]florbetaben 30 AD patients,
20 MCI patients
Compared to controls, increased florbetaben binding was seen in
prefrontal, orbitofrontal, cingulate, parietal, occipital, and temporal
cortical areas, in addition to the putamen, thalamus, and caudate
nuclei. A similar pattern was shown for MCI in the ventrolateral
prefrontal, orbitofrontal, posterior cingulate, parietal, lateral
temporal cortex, and the putamen.
(Continues)
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convert to AD than prodromal patients who were classified as ‘amy-
loid negative’ (Okello, Koivunen, et al., 2009).
Noted strengths of [11C]PiB include high amyloid selectivity and
affinity, but technical limitations hinder its clinical use in centres without
in-house cyclotrons such as its short decay half-life (Yeo, Waddell,
Khan, & Pal, 2015). Additionally, there are significant operational costs
associated with the construction and maintenance of a cyclotron on-site
(Chuck et al., 2005). Data also question the sensitivity of [11C]PiB for the
detection of early amyloid pathology when compared to cerebrospinal
fluid (CSF) Aβ42 biomarkers. Specifically, it was found on the trajectory of
normal ageing that decreased levels of CSF Aβ42 are present before the
manifestation of elevated PiB binding (Morris et al., 2010).
2.2 | 18F-labelled amyloid tracers
To overcome the inherent impracticalities of [11C]PiB, three novel
18F-labelled amyloid tracers have been developed: [18F]florbetapir
(Amyvid), [18F]florbetaben (Neuraceq), and [18F]flutemetamol
(Vizamyl) (Table 1). [18F]flutemetamol has a similar neurochemical
composition to [11C]PiB and is actually a derivative of it (Nelissen
et al., 2009), whereas [18F]florbetapir and [18F]florbetaben are based
on the organic compound stilbene (Hatashita et al., 2014). These
tracers display a substantially longer half-life than that of [11C]PiB,
specifically 110 compared to 20 min. This factor in particular removes
the main barrier faced by imaging facilities in pursuing in vivo amyloid
quantification for clinical use (Jovalekic, Bullich, Catafau, & de Santi,
2016). Moreover, in 2011, the Food and Drug Administration
approved use of [18F]florbetapir to aid in the diagnostic process in AD
(Yang, Rieves, & Ganley, 2012).
In line with its suggested clinical utility, the most widely investi-
gated 18F-labelled amyloid tracer is [18F]florbetapir (Figure 1). It was
shown to be comparable to [11C]PiB, with a high degree of correlation
between the two in terms of cortical binding (Landau et al., 2014;
TABLE 1 (Continued)
Study Amyloid tracer Study population Main findings
Vandenberghe
et al. (2010)
[11C]PiB
[18F]
flutemetamol
27 AD patients,
20 aMCI patients,
15 healthy controls
Tracer uptake in cortical areas including lateral frontal, lateral
temporal, medial temporal, occipital, lateral parietal, and cingulate,
in addition to the striatum, but not the pons and subcortical white
matter, differentiated AD patients and controls. Regional
correlations were also shown with [18F]flutemetamol and PiB
uptake.
Villemagne
et al. (2012)
[11C]PiB
[18F]florbetaben
10 AD patients,
10 healthy controls
For AD patients, both tracers demonstrated significantly higher
uptake compared to controls in the prefrontal, orbitofrontal, gyrus
rectus, cingulate, parietal, lateral occipital, temporal cortex, in
addition to the caudate and putamen. However, uptake was
shown in the thalamus for [11C]PiB but not [18F]flutemetamol.
Lowe et al. (2017) [11C]PiB
[18F]
flutemetamol
21 AD patients, 30 young
cognitively normal
subjects,
31 elderly cognitively
normal subjects
In the cingulate, caudate, precuneus, insula, medial temporal cortex,
occipital cortex, orbitofrontal cortex, pallidum, paracentral lobule,
parietal cortex, postcentral cortex, precentral cortex, prefrontal
cortex, primary visual cortex, putamen, rolandic operculum,
supplementary motor area, and thalamus higher tracer retention
for both [18F]flutemetamol and [11C]PiB was found in AD patients
compared to controls.
Abbreviations: AD, Alzheimer's disease; aMCI, amnestic mild cognitive impairment; FDG, [18F]fludeoxyglucose; MCI, mild cognitive impairment; PET,
positron emission tomography.
TABLE 2 Studies examining in vivo regional brain uptake using amyloid tracers in studies including amyloid positive MCI
Study Tau tracer Study population Main findings
Okello, Koivunen
et al. (2009)
[11C]PiB 31 MCI patients
(17 amyloid positive
and 14 amyloid
negative), 26 healthy
controls
Compared to healthy controls, elevated cortical tracer retention was found in
the frontal, parietal, temporal, occipital, posterior, and anterior cingulate
cortex in MCI patients. Then, 14 of 17 (82%) of amyloid positive MCI patients
converted to AD, while only 1 out of 14 of amyloid negative cases converted.
Converters displayed higher cortical binding in anterior cingulate and frontal
areas.
Hatashita
et al. (2014)
[11C]PiB
[18F]flutemetamol
36 AD patients,
68 MCI patients,
41 healthy controls
Compared to healthy controls, increased uptake for both tracers was noted in
the lateral temporal cortex, anterior cingulate gyrus, frontal cortex, occipital
cortex, posterior cingulate gyrus, precuneus, parietal cortex, and sensorimotor
cortex in AD. Then, 35 out of 36 AD patients (97.2%) were rated as amyloid
positive; 29 out of 68 MCI patients (42.6%) were rated as amyloid positive.
No differences were found in MCI patients versus healthy controls. This could
be due to the evidenced bimodal SUVR distribution of MCI patients.
Abbreviations: AD, Alzheimer's disease; MCI, mild cognitive impairment; SUVR, standardised uptake value ratio.
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Wolk et al., 2012). In a group of individuals with a life expectancy of
no more than 6 months, [18F]florbetapir showed a sensitivity and
specificity of 92 and 100%, respectively, in detecting a significant
degree of amyloid plaques. Moreover, the accumulation of amyloid
detected by in vivo PET imaging correlated with amyloid pathology
measured from brain tissue post-mortem (Clark et al., 2012). In AD,
frontal, temporal, occipital, parietal, cingulate, and precuneus cortical
areas all show increased amyloid retention as measured by this ligand
compared to healthy controls. This finding also holds for MCI patients
in the posterior cingulate cortex (Camus et al., 2012). A strong dis-
criminative ability of [18F]florbetapir for AD and MCI compared to a
cognitively normal status is supported by a number of additional stud-
ies (Degenhardt et al., 2016; Johnson et al., 2013; Namiki et al., 2015).
MCI patients rated as Aβ positive using this tracer demonstrated
greater longitudinal decline in measures of global cognition, cognitive
processing speed, and verbal fluency when compared to Aβ negative
patients. AD patients rated as Aβ positive showed a similar pattern on
measures of global cognition and verbal fluency (Doraiswamy et al.,
2014). Moreover, a positive amyloid scan for MCI patients indicates a
greater risk of disease progression to AD (Doraiswamy et al., 2012).
While 18F-labelled amyloid tracers are equivalent in their degree of
diagnostic accuracy (Morris et al., 2016), [18F]florbetapir shows partic-
ularly fast brain kinetics relative to others (Wong et al., 2010). When
considering the clinical implementation of this modality, recent evi-
dence demonstrates its cost-effectiveness (Hornberger, Bae, Watson,
Johnston, & Happich, 2017) and meaningful impact on the diagnostic
confidence for AD by physicians (Boccardi et al., 2016).
While not as widely investigated as [18F]florbetapir, a similar pat-
tern of amyloid retention is demonstrated throughout the cortex in
AD using both [18F]florbetaben (Barthel et al., 2011) and [18F]
flutemetamol (Nelissen et al., 2009). Although it is not a stilbene deriv-
ative, it is important to note that [18F]flutemetamol has demonstrated
dosimetry comparable with other 18F-labelled radiopharmaceuticals
(Heurling, Leuzy, Zimmer, Lubberink, & Nordberg, 2016). Additional
commonalities shared by these two tracers with [18F]florbetapir
include high rates of sensitivity and specificity in diagnosing AD
(Barthel et al., 2011; Hatashita et al., 2014; Rowe et al., 2008; Tiepolt
et al., 2013; Vandenberghe et al., 2010; Villemagne et al., 2011) and
detecting amyloid pathology later confirmed at post-mortem
(Ikonomovic et al., 2016; Sabri et al., 2015; Thal et al., 2015), compara-
ble diagnostic utility to [11C]PiB (Lowe et al., 2017; Villemagne et al.,
2012), effectiveness in the prediction of conversion from MCI to AD
(Ong et al., 2015; Wolk et al., 2018), and the clinical benefit of
increased dementia diagnostic confidence (Schipke et al., 2012; Zwan
et al., 2017). Associations are shown between Aβ uptake and cogni-
tive dysfunction in AD (Barthel et al., 2011) and MCI (Bahar-Fuchs
et al., 2013) for [18F]florbetaben. However, there is a still a strong
need to further validate [18F]flutemetamol using standardised neuro-
psychological assessments. Additionally, research suggests that there
is a diagnostic advantage of combining structural MRI and PET imag-
ing with this ligand in AD and MCI (Thurfjell et al., 2012).
There is some disagreement between studies regarding the mea-
surement of Aβ deposition using in vivo PET. This is due to a range of
factors including variability in scanning time, methodology employed
during analyses, identified reference regions and regions of interest,
attenuation correction, partial volume correction, machines used to
scan, and tracer-specific properties. This has led to some uncertainty
regarding a consistent definition of abnormal amyloid levels character-
istic of AD (Klunk et al., 2015). In support, Villeneuve et al. found that
routinely established thresholds for Aβ positivity using [11C]PiB were
insensitive and likely to lead to false negatives (Villeneuve et al.,
2015). There has been an attempt to solve this problem through the
creation of a standardised outcome measure across amyloid-PET
modalities measured in units termed ‘Centiloids’ ranging from 0 to
100 (Klunk et al., 2015). However, there is still a great deal of variabil-
ity present in the amyloid positivity thresholds derived from this
approach (Su et al., 2018). A further limitation of amyloid PET imaging
modalities is that there is a lack of concordance with Aβ plaque phases
as determined by pathohistological methodology, such as Thal stages
(Thal, Rüb, Orantes, & Braak, 2002). For example, [18F]flutemetamol
F IGURE 1 Positron emission
tomography (PET) imaging as
quantified by standardised uptake
values (SUVs) depicting increased
tracer uptake for [18F]florbetapir
and [18F]AV-1451 in an
Alzheimer's disease (AD) patient
and a mild cognitive impairment
(MCI) patient compared to a
healthy control [Color figure can
be viewed at
wileyonlinelibrary.com]
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PET was unable to accurate predict the target Aβ stages in 27.84% of
cases in an end-of-life cohort (Thal et al., 2018). Additionally, an amy-
loid positivity threshold of a standardised uptake value ratio of 1.5
was not sensitive to MCI patients in Thal Phase 1 or 2, and just lower-
ing this value by 0.2 led to approximately 75% of healthy control sub-
jects being classified as having significant brain amyloidosis (Ismail
et al., 2019).
3 | TAU STUDIES
Advances in the measurement of tau pathology in humans using in
vivo PET radioligands are scarce, but recent, when compared to their
amyloid-specific counterparts. For years, the gold standard in quanti-
fying tau-derived pathology was either histopathological analysis from
post-mortem tissue or the invasive collection of tau and phosphory-
lated tau from the CSF by means of lumbar puncture (Saint-Aubert
et al., 2017). This delay in applying a tau ligand was due to several
major challenges that were inherently present in the imaging of tau.
Unlike amyloid, tau is intracellular, so potential ligands need to be able
to cross both the blood–brain barrier and the plasma cell membrane
of the neurone. In comparison to amyloid pathology, tau aggregates
are present in lower concentrations throughout the brain; therefore,
ligands are required to have higher specificity for tau. Additionally, tau
has multiple protein conformations and isoforms, which could poten-
tially adversely impact sites for ligand binding (Bischof, Endepols, van
Eimeren, & Drzezga, 2017).
The first breakthrough in tau imaging using PET was made using
the radioligand [18F]FDDNP. However, this methodology concomi-
tantly assesses amyloid plaque burden and cannot be considered a
truly selective for tau pathology (Shoghi-Jadid et al., 2002), and was
later shown to have poor binding affinity for NFTs (Thompson et al.,
2009). Since then, four families of tracers in particular have shown
promise in the assessment of AD and MCI: [11C]PBB3, from the same
tracer family as [11C]PiB, the THK aryquinoline derivatives, the
pyrido-indole derivative [18F]AV-1451, and recently developed
second-generation tau tracers (Table 3).
3.1 | [11C]PBB3 and THK tracers
Maruyama et al. validated the use of [11C]PBB3, a pyridinated ben-
zothiazole, in providing high-contrast imaging of tau inclusions in both
animals and AD patients. Using a limited sample of three AD patients
and three healthy controls, higher tracer accumulation was reported
in medial temporal brain areas of AD patients compared to controls.
This included the hippocampus (Maruyama et al., 2013). In vivo tau
burden as detected by this ligand is associated with grey matter atro-
phy and cognitive impairment (Shimada et al., 2017).
Research suggests that radiotracers from the THK family bind to a
different site than that of [11C]PBB3 (Lemoine et al., 2017). The latter
may be more selective to tau aggregations that have a spatial relation-
ship with amyloid deposits, while the former may show preference for
tau closely linked to brain atrophy, CSF tau, and neuropsychological
functioning (Chiotis et al., 2018). The first generation of THK radio-
ligands included [18F]THK523, [18F]THK5105, and [18F]THK5117, but
demonstrated several flaws that hindered their clinical utility including
poor disease discriminability and high white matter retention. Having
overcome these limitations, [18F]THK5317 and [18F]THK5351 may be
particularly useful in clinical practice (Saint-Aubert et al., 2017). [18F]
THK5317 shows a good ability to differentiate between AD and MCI
patients and healthy controls with a pattern of regional uptake that
includes selected areas in the temporal, frontal, occipital, and parietal
cortex, in addition to the precuneus (Chiotis et al., 2016). Similar
results are shown with [18F]THK5351 with particularly high retention
in temporal brain areas (Harada et al., 2016; Lockhart et al., 2016). A
direct comparison of these two tracers revealed that [18F]THK5351
has a superior pharmacokinetic profile and greater dissociation from
white matter and cerebellar grey matter (Betthauser et al., 2017).
However, regional [18F]THK5317 binding has shown an inverse rela-
tionship with measures of performance on global cognition and epi-
sodic memory (Saint-Aubert et al., 2016). One should interpret results
from THK tracers with caution, given evidence that they bind to
monoamine oxidase (MAO). For example, in AD, cortical [18F]
THK5351 binding was associated with MAO-B measured in post-
mortem brain tissue. Moreover, an MAO-B inhibitor was shown to
actively block THK5351 binding in vivo (Harada et al., 2018). Results
from another study indicated the detection of suspected off-target
MAO-B binding for [18F]THK5317 in a study of five AD patients
(Murugan et al., 2019).
3.2 | [18F]AV-1451
Compared to [18F]THK5317, [18F]AV-1451 (flortaucipir) which is also
referred to as [18F]T807, has a clearer pattern of cortical uptake in AD
patients and demonstrates a lower degree of off-target binding (Jang
et al., 2018) (Figure 1). However, larger effect sizes for cerebellar
uptake were noted relative to [18F]THK5351 (Chen et al., 2018). Bind-
ing of this radioligand mirror the distribution of NFT pathology across
the Braak stages (Marquié et al., 2017), and was reduced in areas
characterised by Aβ neuritic plaques (Lowe et al., 2016). One study
found a classification rate of 85.7% for [18F]AV-1451 in making an
accurate clinical diagnosis, including AD and MCI (Passamonti et al.,
2017). This tracer also demonstrates high sensitivity and specificity in
discriminating AD patients and healthy controls (Maass et al., 2017;
Wang et al., 2016). In AD, a similar pattern of cortical uptake is found
compared to other tau-based ligands, whereas patients with MCI
demonstrate a more localised pattern of tau deposition in entorhinal
regions (Cho et al., 2016; Johnson et al., 2016). While a strength of
this radioligand is its specificity for NFT pathology, limitations that
pertain to off-target binding should be acknowledged. A autoradio-
graphic evaluation of [18F]AV-1451 demonstrated that sites exhibiting
off-target binding included the meninges, scalp, basal ganglia, choroid
plexus calcifications, blood vessels and potentially red blood cells,
areas characteristic of iron deposition, and leptomeningeal melanin
(Lowe et al., 2016).
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TABLE 3 Studies examining in vivo regional brain uptake using tau tracers in AD and MCI
Study Tau tracer Study population Main findings
Maruyama et al.
(2013)
[11C]PBB3 Three AD patients, three
cognitively normal subjects
Medial temporal regions, including the hippocampus, demonstrated
consistently greater [11C]PBB3 retention in AD when compared to
controls.
Shimada et al.
(2017)
[11C]PBB3 17 AD patients, 9 MCI
patients, 28 healthy
controls
Notable differences in tracer uptake were observed in neocortical areas,
and particularly the medial temporal cortex for those on the spectrum of
AD compared to healthy controls. Medial temporal atrophy on MRI was
also observed for this group. Moreover, for those along the spectrum of
AD, uptake in frontal and temporo-parietal junctions were negatively
associated with cognitive status, uptake in limbic, paralimbic, and
frontoparietal areas were positively associated with dementia status,
and uptake in frontal regions was positively associated with frontal
executive dysfunction.
Chiotis et al.
(2018)
[11C]PBB3
[11C]THK5351
Four AD patients, five MCI
patients
In a mixed group of AD and MCI patients, [11C]THK5351 showed greater
uptake in medial versus lateral temporal lobe, whereas the inverse was
shown for [11C]PBB3. [11C]PBB3 correlated with PET amyloid uptake.
[11C]THK5351 and [11C]PBB3 regional uptake was negative correlated
with cognitive performance.
Chiotis et al.
(2016)
[18F]THK5317 9 AD patients, 13 MCI
patients, 9 healthy controls
Both MCI and AD patients showed increased tau binding in inferior
temporal, lateral temporal, lateral occipital, inferior parietal, anterior
frontal, lateral occipital cortex, in addition to the precuneus compared to
healthy controls. Negative correlations between tau retention and FDG
uptake were observed in the frontal cortex, while areas of the
neocortex showed positive correlations between tau and amyloid
binding on PET.
Lockhart et al.
(2016)
[18F]THK5351 10 AD patients, 6 healthy
controls
Regions including eroded white matter, fusiform gyrus, inferior temporal
cortex, lingual gyrus, middle temporal gyrus, occipital cortex, parietal
cortex, posterior cingulate, and precuneus demonstrated higher tracer
uptake for AD patients relative to healthy controls.
Saint-Aubert et al.
(2016)
[18F]THK5317 9 AD patients, 11 MCI
patients
[18F]THK5317 binding in the parahippocampal, fusiform, inferior, middle
and superior temporal gyri, in addition to occipital areas, the middle
frontal and posterior cingulate gyri, the parietal operculum, and
precuneus were negatively related to cognition for patients along the
AD continuum. Outcomes on FDG–PET showed a similar relationship
with tau binding and mediated the effects of in vivo tau binding on
cognition.
Chen et al. (2018) [18F]THK5351
[18F]AV-1451
[18F]THK5351: 8 AD patients,
9 healthy controls
[18F]AV-1451:12 AD patients,
12 healthy controls
Relative to healthy controls, [18F]THK5351 uptake was increased in
temporal and occipital cortical areas whereas [18F]AV-1451 uptake was
elevated in the temporal cortex for AD patients.
Passamonti et al.
(2017)
[18F]AV-1451 15 AD and MCI patients,
13 healthy controls
Compared to healthy controls, those on the AD spectrum exhibited
increased binding in all four lobes of the cortex and in the hippocampus.
Wang et al. (2016) [18F]AV-1451 59 AD patients and healthy
controls
Tracer retention was increased in hippocampal and widespread cortical
regions in AD patients when compared to controls.
Cho et al. (2016) [18F]AV-1451 20 AD patients, 15 MCI
patients, 20 healthy
controls
Relative to controls, the majority of cortical regions assessed
demonstrated higher tau uptake in AD. This pattern held for the
entorhinal cortex in MCI.
Johnson et al.
(2016)
[18F]AV-1451 19 AD and MCI patients,
57 cognitively normal
subjects
In a combined patient group, those with AD and MCI showed increased
cortical retention of [18F]AV-1451 in temporo-parietal, parieto-occipital,
precuneus posterior cingulate, and frontal regions compared to controls.
Moreover, differences were shown in entorhinal, parahippocampal,
inferior temporal, and fusiform cortex. In the patient group, increased
inferior temporal uptake was associated with cognitive impairment and
dementia severity.
Pontecorvo et al.
(2017)
[18F]AV-1451 48 AD patients, 95 MCI
patients, 58 older
cognitively normal subjects
In frontal, occipital, parietal, and temporal cortex, in addition to the
amygdala, anterior hippocampus, anterior and posterior
parahippocampus, and fusiform areas AD and MCI patients showed
elevated levels of tau binding versus controls.
(Continues)
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Strong evidence implicates tau pathology as measured by [18F]
AV-1451 in the manifestation of dementia-related cognitive impair-
ment. For example, Pontecorvo et al. show that in a mixed group of
Aβ positive subjects, increased tau ligand binding was correlated with
global deteriorations in cognition as assessed by the Mini Mental Sta-
tus Exam (MMSE) and Alzheimer's Disease Assessment Scale-
Cognitive Subscale (ADAS-Cog) (Pontecorvo et al., 2017). Increased
regional tau uptake has also shown associations with impaired
domain-specific neuropsychological performance including memory,
language, and visuospatial abilities in numerous variants of AD
(Ossenkoppele et al., 2016). Interestingly, patients with a high degree
of retention in the entorhinal cortex displayed particularly poor mem-
ory functioning (Whitwell et al., 2018). A recent study also links tau
burden quantified by [18F]AV-1451 to neurodegeneration, specifically
longitudinal brain atrophy (Das et al., 2018). Other neurodegenerative
pathology shows unique profiles of tau aggregation as detected by
this tracer. For example, patients diagnosed with corticobasal syn-
drome show retention increases in frontal and parietal cortices com-
pared to those with MCI due to AD (Niccolini et al., 2018).
Considering atypical manifestations of AD, those with posterior corti-
cal atrophy display more cortical uptake in occipital areas relative to
logopenic progressive aphasia (lvPPA) patients, whilst lvPPA is
characterised by more temporal and frontal uptake (Tetzloff et al.,
2018). Despite having a favourable pharmacokinetic profile and speci-
ficity for tau, further study is required in determining the clinical utility
of in vivo imaging using [18F]AV-1451 in AD and MCI (Chien et al.,
2014; Zhang et al., 2012).
3.3 | Second-generation tau tracers
There is a fast pace of development in the tau PET imaging literature
with several novel second-generation tracers currently in develop-
ment and undergoing validation (Bischof et al., 2017). Evidence indi-
cates numerous advantages attributed to some of these emergent tau
tracers, including having a characteristically low relative affinity for
MAO-B in silico (Murugan et al., 2019). One promising second-
generation tau tracer is [18F]MK-6240. A high binding affinity was
shown to tau deposits specifically in the brain tissue of AD patients,
but not to those in the tissue of patients with other tauopathies or
TDP-43, Aβ, and α-synuclein. However, off-target binding to
neuromelanin was indicated (Aguero et al., 2019). Cortical tau binding
for this tracer was two to three times higher in AD subjects compared
to healthy controls (Lohith et al., 2019). [18F]PI-2620 is another
recently developed ligand that shows patterns of tau binding in parie-
tal and temporal lobe, in addition to the precuneus and posterior cin-
gulate in AD. A notable lack of off-target binding, which was an issue
TABLE 3 (Continued)
Study Tau tracer Study population Main findings
Whitwell et al.
(2018)
[18F]AV-1451 39 typical AD patients Patients with typical AD demonstrated variability in entorhinal and
neocortical tau binding; however, in a cluster analysis comparing high
and low uptake groups, those with high entorhinal and neocortical
tracer retention showed greatest memory impairment, whilst those with
low entorhinal and high neocortical binding showed greatest impairment
in other neuropsychological domains.
Murugan et al.
(2019)
[18F]THK5317 Five AD patients AD patients demonstrated [18F]THK5317 binding in the basal ganglia and
thalamus, in addition to the midbrain. Tracer retention was also shown
in the isocortical temporal lobe and areas in the lateral parietal and
frontal lobes.
Lohith et al.
(2019)
[18F]MK-6240 Four AD patients, two MCI
patients, four healthy
controls
Higher tracer uptake was generally demonstrated in primarily medial
temporal lobe areas that included the amygdala, hippocampus, and
parahippocampal gyrus in AD/MCI subjects. In two AD subjects in
advanced disease stages, uptake was also found in neocortical temporal,
frontal, and parietal areas.
Kroth et al. (2019) [18F]PI-2620 Four AD patients, two healthy
controls
Three AD subjects showed asymmetric distributions of tracer retention in
temporal regions, the precuneus, and post-cingulate. One AD subject
who was in a very mild stage of the disease demonstrated no uptake.
Wong et al. (2018) [18F]RO-948 11 AD patients, 4 older
controls
AD patients had increased tracer binding relative to older controls in the
right hippocampus, entorhinal area, parahippocampus, left middle
frontal lobe, fusiform gyrus, middle temporal cortex, inferior temporal
lobe, and right inferior parietal lobe.
Bohórquez et al.
(2019)
[18F]GTP1 65 patients on the spectrum
of AD (ranging from
prodromal to moderate
stages), 15 cognitively
normal individuals
Compared to CN individuals, in all AD patients, Braak Stage I/II brain
regions demonstrated higher tracer uptake, and in mild and moderate
patients on the AD spectrum Braak Stage V/VI regions had elevated
tracer retention.
Abbreviations: AD, Alzheimer's disease; FDG, [18F]fludeoxyglucose; MCI, mild cognitive impairment; MRI, magnetic resonance imaging; PET, positron
emission tomography.
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faced by tau tracers from prior generations, was also demonstrated
(Kroth et al., 2019; Stephens et al., 2018). [18F]JNJ311 and [18F]JNJ-
067 are structurally different from existing tau tracers and published
in vivo data on this JNJ family of radioligands is currently unavailable
(Leuzy et al., 2019). Wong et al. evaluated three potential tau tracers
in amyloid positive AD patients and controls: [11C]RO-963, [11C]RO-
643, and [18F]RO-948. Among the three, only [18F]RO-948 was rec-
ommended for further investigation as minimal binding was found in
controls and patients with AD had region-specific patterns of tracer
uptake consistent with pathohistological data for the spread of tau
pathology (Wong et al., 2018). Not only does [18F]GTP1 retention cor-
respond to established patterns of brain tau distribution in AD, but
this new second-generation tau tracer was also correlated with per-
formance on cognitive measures, particularly in the earliest stages of
AD (Bohórquez et al., 2019; Teng et al., 2018; Teng et al., 2019).
4 | NEUROINFLAMMATION/
TRANSLOCATOR PROTEIN STUDIES
It has been known for some time from the results of histopathological
studies that activated microglia localise to Aβ plaques (Perlmutter,
Barron, & Chui, 1990) and NFTs (Sheffield, Marquis, & Berman, 2000).
Moreover, the results of a genome-wide association study has impli-
cated the triggering receptor expressed on myeloid cells 2 (TREM2)
gene, which encodes a microglial cell surface protein, as the second
most significant risk factor for late onset AD after APOE ε4 (Guerreiro
et al., 2013). This has stimulated much research into elucidating the
role of inflammation in the pathogenesis of AD.
Advances in the in vivo quantification of neuroinflammation have been
made through the investigation of translocator protein 18 kDa (TSPO) as a
PET imaging target. Throughout the CNS, TSPO is present in glial and
ependymal cells and is located on the outer membrane of mitochondria. It
is posited that TSPO is involved in a range of cell-based functions, including
cholesterol transport and hormone synthesis (Papadopoulos et al., 2006).
However, its exact role and functional significance in relation to the brain
immune response is not fully understood. Under normal physiological con-
ditions, there is a low expression of TSPO limited to glial cells. Neverthe-
less, during neuronal injury or insult, when microglia are activated, TSPO
levels in turn experience a significant upregulation (Rupprecht et al., 2010).
Moreover, immunohistochemistry studies have confirmed that TSPO
upregulation and microglia activation co-localise spatially following a neu-
rotoxic intervention, suggesting that TSPO can measure neu-
roinflammation through the detection of activated microglia (Kuhlmann &
Guilarte, 2000). Beyond microglia, increased TSPO expression is also
observed in reactive astrocytes (Rupprecht et al., 2010). While numerous
TSPO radioligands have been developed so far, we will focus on those
investigated in AD/MCI patient populations.
4.1 | [11C]PK11195
The most thoroughly researched TSPO radiotracer is [11C]PK11195
(Table 4). In a pioneering study, Cagnin et al. demonstrated that
patients with AD had a signature pattern of [11C]PK11195 uptake in
brain areas that included the cingulate, temporoparietal, and entorhi-
nal cortex (Cagnin et al., 2001). Since then, results from this tracer
have been mixed and somewhat contradictory. Minimal or small clus-
ters of increased binding in MCI and mild to moderate AD was
reported in two studies (Schuitemaker et al., 2013; Wiley et al., 2009).
These authors speculated that either microglial activation is implicated
later in the disease course or [11C]PK11195 is not a sensitive marker
of such activity. However, these claims are challenged by findings
from studies that used region of interest-based analyses to show
widespread tracer uptake throughout the cortex for AD patients
(Edison et al., 2008; Fan, Aman, et al., 2015; Passamonti et al., 2018),
particularly in parietotemporal areas (Yokokura et al., 2011) and for
MCI patients especially in the frontal cortex (Fan, Aman, et al., 2015;
Okello, Edison, et al., 2009). The neurodegenerative effects of this
potentially prolonged immune response are hinted at when consider-
ing that increased tracer retention has been linked with hippocampal
atrophy (Femminella et al., 2016). Utilising [11C]PK11195, longitudinal
research suggests an initial reduction of microglial activation in pro-
dromal disease stages (Fan et al., 2017) contrasting with a subsequent
increase in microglial activation in AD during disease progression (Fan,
Okello, et al., 2015).
Results pertaining to the relationship between [11C]PK11195
binding and cognitive status are also conflicting. Three studies found
inverse correlations between MMSE score and tracer uptake (Edison
et al., 2008; Fan, Aman, et al., 2015; Yokokura et al., 2011) and one
demonstrates a negative correlation between tracer uptake in the
precuneus and episodic memory performance measured by the Rey
Auditory Verbal Learning Test (Passamonti et al., 2018), which sug-
gests a role for microglial activation in disease severity. However,
others failed to find similar associations between [11C]PK11195
retention and neuropsychological performance (Schuitemaker et al.,
2013; Yokokura et al., 2017). This pattern of contradictory results
could possibly be attributed to small sample sizes, limitations of the
tracer and variability in study methodology.
Several technical limitations of [11C]PK11195 were found, including
its short half-life of approximately 20 minutes that is a barrier for cen-
tres without a costly on-site cyclotron, low brain uptake, and impor-
tantly low signal to noise ratio. It also exhibits a high degree of
nonspecific binding (Ching et al., 2012). This nonspecific binding may
apply to targets including brain-based lipids (Hatty et al., 2014) and
α1-acid glycoprotein (Lockhart et al., 2003). Additional clinical transla-
tion difficulties are imposed on the molecule through carbon-11 label-
ling (Chauveau, Boutin, Van Camp, Dollé, & Tavitian, 2008). However,
suboptimal modelling of this tracer is likely its most pressing concern as
there has been substantial difficulty in the definition of a true reference
region, which is an area absent of binding, for [11C]PK11195 (Chauveau
et al., 2008). When using an arterial plasma input function, the use of a
reference region allows for valid quantification of binding potential
(Cunningham, Parker, Rabiner, Gee, & Gunn, 2005). In fact, variability in
the findings of studies discussed using [11C]PK11195 could, at least in
part, reflect the use of various and inconsistent methods for reference
region quantification. To account for this issue, an automatic supervised
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TABLE 4 Studies examining in vivo regional brain uptake using TSPO tracers in AD and MCI
Study TSPO tracer Study population Main findings
Cagnin
et al. (2001)
[11C]PK11195 8 AD patients,
15 healthy
controls
Elevated levels of tracer level were observed in brain areas including the
fusiform gyri, left parahippocampal gyrus, left posterior cingulate, inferior and
middle temporal gyri, left amygdala, inferior parietal lobules, and to a lesser
degree putamen and right pallidum in AD patients when compared to controls.
In particular, uptake in the left inferior temporal lobe differentiated AD
patients with a sensitivity of 75%.
Schuitemaker
et al. (2013)
[11C]PK11195 19 AD patients,
10 MCI patients,
21 healthy
controls
The only brain region assessed that showed any difference in [11C]PK11195
binding between AD patients and controls was the bilateral occipital cortex,
where patients showed more binding. No such differences were found when
comparing MCI patients to controls.
Wiley et al. (2009) [11C]PK11195 Six patients with AD,
six patients MCI
patients, five
healthy controls
No difference in TSPO binding was found when comparing groups on the AD
spectrum with controls in any brain region.
Edison et al. (2008) [11C]PK11195 13 AD patients,
10 healthy
controls
Relative to healthy controls, areas in frontal temporal, parietal, and occipital
association cortex, in addition to the cingulate and striatum, showed increased
tracer uptake in AD patients. Inverse correlations between uptake in posterior
cingulate, parietal, and frontal cortical areas and global cognition were found.
Passamonti
et al. (2018)
[11C]PK11195 16 AD and MCI
patients,
13 healthy
controls
In a combined group of AD and MCI patients, increased binding was found in
brain areas within the occipital, parietal, and temporal cortex, in addition to
medial temporal regions including the hippocampus and amygdala. Binding in
the precuneus was negatively associated with performance on a measure of
delayed recall.
Yokokura
et al. (2011)
[11C]PK11195 11 AD patients,
10 healthy
controls
Medial frontal, parietal, and left temporal cortical areas demonstrated higher
[11C]PK11195 retention for AD patients compared to controls. Additionally,
uptake in the left anterior cingulate, left precuneus, left hippocampus, and left
medial frontal cortex showed negative association with global cognitive
performance. A similar inverse relationship was found for regional TSPO
binding in the posterior cingulate cortex and amyloid uptake on [11]C-PiB in
this region.
Okello, Edison
et al. (2009)
[11C]PK11195 14 MCI subjects,
10 healthy
controls
Frontal cortical regions showed increased TSPO binding for MCI patients when
compared to controls.
Fan, Brooks, Okello,
and Edison (2017)
[11C]PK11195 8 AD patients, 8 MCI
patients,
14 healthy
controls
After a period of 14 months, MCI patients showed reductions in [11C]PK11195
in areas including temporal, occipital, parietal, cingulate cortex, and the
hippocampus. AD patients showed an increase of approximately 36% in
microglial activation relative to controls over this same period of time.
Femminella et al.
(2016)
[11C]PK11195 Eight AD patients,
eight healthy
controls
In AD, [11C]PK11195 uptake in medial temporal regions and the hippocampus
was negatively associated with hippocampal volume as measured by MRI.
Fan, Aman
et al. (2015)
[11C]PK11195 10 AD patients
10 MCI patients,
16 healthy
controls
Cortical retention of [11C]PK11195 in areas including the occipital lobe,
temporal lobe, hippocampus, parahippocampus, temporal, and precentral and
postcentral gyrus was 36–52% higher in AD patients compared to controls.
Regions including the temporal, frontal, orbital, straight, parietal gyrus, insula,
putamen, and occipital lobe were 28–36% higher in MCI relative to controls.
Throughout the four lobes of the cortex, and the insula, thalamus, and
hippocampus microglial activation and amyloid load measured by [11C]PiB
were positively correlated, a similar but not as widespread relationship was
evidenced in MCI. TSPO uptake in frontal, temporoparietal, and occipital
cortex was negatively correlated with global cognition, while regional
associations were also found with cerebral glucose hypometabolism on FDG
PET.
Yokokura
et al. (2017)
[11C]PK11195
[11C]DPA-713
[11C]-PK11195:
10 AD patients,
10 healthy elderly
controls
In temporal, occipital, parietal, frontal, cingulate, parahippocampal, in addition to
the cerebellum, hippocampus, amygdala, caudate, putamen, and thalamus
showed greater [11C]DPA-713 uptake than controls; however when using
[11C]PK11195 only the precuneus showed this pattern. While regional [11C]
(Continues)
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TABLE 4 (Continued)
Study TSPO tracer Study population Main findings
[11C]DPA-713:7 AD
patients,
12 healthy elderly
controls
DPA-713 uptake demonstrated an inverse relationship with cognition, no such
significant relationship was shown using [11C]PK11195.
Yasuno et al. (2008) [11C]
DAA1106
10 AD patients,
10 healthy
controls
[11C]DAA-1106 binding was upregulated in the cerebellum, prefrontal cortex,
parietal cortex, temporal cortex, occipital cortex, anterior cingulate cortex, and
striatum in AD patients compared to controls.
Kreisl et al. (2013) [11C]PBR28 19 AD patients,
10 MCI patients,
13 healthy
controls
[11C]PBR28 binding was elevated in prefrontal, inferior parietal, temporal,
precuneus, posterior cingulate, occipital, hippocampus, entorhinal cortex in
AD patients compared to controls. No such effects were found for MCI
patients. Region-specific binding was positively associated with worse
performance on global cognition, dementia severity, memory, visuospatial
ability, and executive functioning. A similar relationship was found in AD with
tracer uptake and brain atrophy.
Lyoo et al. (2015) [11C]PBR28 25 AD patients,
11 MCI patients,
21 healthy
controls
Compared to healthy controls, temporal and parietal brain areas demonstrated
significantly higher uptake in AD patients. Relative significant differences for
MCI patients were not evidenced.
Hamelin et al. (2016) [18F]DPA-714 64 AD patients,
32 healthy
controls
Patients with AD, including the prodromal form, demonstrated greater tracer
uptake in regions that include the precuneus, parietal, temporal cortex, and
medium and posterior cingulate compared to controls. This uptake was
positively associated with performance on global cognition and grey matter
volume. This also holds for regional amyloid uptake.
Suridjan et al. (2015) [18F]FEPPA 21 AD patients,
21 healthy
controls
Temporal, frontal, parietal, and occipital cortical regions and the hippocampus
demonstrated increased tracer retention for AD patients compared to
controls. This also held for the posterior limb of the internal capsule and the
cingulum bundle. Regional uptake was associated with impairment in
visuospatial ability and language ability.
Varrone et al. (2015) [18F]FEMPA 10 AD patients,
7 healthy controls
Analyses revealed that higher [18F]FEMPA uptake was observed in medial
temporal, lateral temporal, and posterior cingulate cortex, in addition to
regions including the putamen, caudate, thalamus, and cerebellum for AD
patients when compared to controls.
Kreisl et al. (2016) [11C]PBR28 14 AD patients,
8 healthy controls
Relative to controls, elevated radiotracer binding was demonstrated in the
inferior parietal lobule, occipital cortex, precuneus, entorhinal cortex,
hippocampus, inferior, and middle temporal cortex for AD patients. Annual
increases in [11C]PBR28 binding ranging from 2.5 to 7.7% was also observed
in AD. Regional increases in patients were positively correlated with dementia
severity, and brain atrophy.
Hamelin et al. (2018) [18F]DPA-714 Baseline: 52 AD
patients,
17 healthy
controls
Follow-up: 21 AD
patients,
13 healthy
controls
At baseline, temporal and parietal brain areas had significantly higher tracer
retention in AD patients relative to controls. Tracer retention was positive
correlated with a worsening of dementia and cognitive status, in addition to
brain atrophy. Annual increases of 13.2% were observed for AD patients in
terms of TSPO tracer binding.
Yasuno et al. (2012) [11C]
DAA1106
10 AD patients,
7 MCI patients,
10 healthy
controls
Compared to controls, MCI patients demonstrated increased TSPO binding in
the striatum, lateral temporal, parietal, and anterior cingulate cortex. This
pattern held for AD in these regions in addition to the medial prefrontal
cortex.
Fan et al. (2018) [11C]PBR28 13 MCI patients,
9 healthy controls
MCI patients had greater tracer uptake in the temporal lobe, post-cingulate
cortex, thalamus, medial temporal lobe, hippocampus, amygdala, and
cerebellum when compared to healthy controls.
Knezevic et al. (2017) [18F]FEPPA 11 aMCI patients,
14 healthy
controls
Region-specific TSPO binding was not significantly different between aMCI
patients and controls. However, there was a positive correlation between
TSPO binding and amyloid binding on [11C]PiB in aMCI in the hippocampus.
(Continues)
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clustering procedure utilising a priori kinetic classes has been developed
to extract grey matter estimates that can be reliably classified as refer-
ence region tissue (Turkheimer et al., 2007).
4.2 | Second-generation TSPO tracers
The shortcomings of [11C]PK11195 were overcome with the advent
of second-generation TSPO ligands, which notably had an improved
signal-to-noise ratio and higher binding affinity compared to [11C]
PK11195 (Edison & Brooks, 2018). While many second-generation
TSPO tracers have been discovered, we will cover only those that
have been most widely used in humans and specifically in AD or MCI.
These include [11C]PBR28, [18F]DPA-714, [18F]FEPPA, [18F]FEMPA,
and [11C]DAA1106 (Table 4). Findings from studies examining neu-
roinflammation, as measured by increased tracer retention, in AD
patients using these newer ligands are more consistent than [11C]
PK11195. Specifically, increased levels of region-specific TSPO bind-
ing in numerous cortical areas are demonstrated in AD patients com-
pared to healthy controls (Hamelin et al., 2016; Kreisl et al., 2013;
Lyoo et al., 2015; Suridjan et al., 2015; Varrone et al., 2015; Yasuno
et al., 2008). The temporal pattern of neuroinflammation over the
course of the AD has also been well-characterised through longitudi-
nal investigations. In AD patients, yearly average increases in TSPO
binding that ranged from 2.5 to 7.7% were shown using [11C]PBR28
(Kreisl et al., 2016), whilst for [18F]DPA-714 an elevated annual
change of 13.2% in tracer binding was displayed (Hamelin
et al., 2018).
A change in role of activated microglia is supported by a large lon-
gitudinal study utilising [18F]DPA-714 (Hamelin et al., 2016; Hamelin
et al., 2018). Participants with MCI and higher initial TSPO binding
had a slower rate of decline measured by the Clinical Dementia Rating
and smaller increase in TSPO binding than those with lower initial
TSPO binding. These results, coupled with the aforementioned [11C]
PK11195 studies, have led to the proposal of a dual peak hypothesis
of neuroinflammation in AD (Fan et al., 2017). This suggests that the
early peak in activated microglia in MCI patients is initially protective,
attempting to remove Aβ, whereas the later peak in activated
microglia is detrimental. Associations between TSPO expression and
clinical outcome for individuals on the spectrum of AD may only be
observable for neuroimaging data collected during rising rather than
declining phases of these peaks. It is important to note that results
from TSPO imaging studies that include MCI patients may reflect
either a rising or declining PET signal. While different phenotypes of
activated microglia are detectable in pathological studies (Tang & Le,
2016), PET imaging utilising TSPO is unable to differentiate the micro-
glial subtype.
Similar to [11C]PK11195, in vivo increases in TSPO binding are
associated with impairments in global cognition and memory (Hamelin
et al., 2018; Kreisl et al., 2013), but also extend to domains that
include visuospatial and language ability, and executive functioning, in
addition to dementia severity and brain atrophy (Hamelin et al., 2018;
Kreisl et al., 2013; Kreisl et al., 2016; Suridjan et al., 2015). However,
some studies demonstrate no such correlations with the ADAS-Cog
or MMSE (Yasuno et al., 2008; Yasuno et al., 2012) whilst one
reported an opposite pattern, where MMSE scores were positively
related to [18F]DPA-714 binding (Hamelin et al., 2016). This latter
result could possibly be attributed to the inclusion of prodromal AD
patients in the study sample. Overall, the nature of the correlation
between inflammatory changes and cognitive performance requires
further investigation. When clarifying regional uptake patterns of
second-generation TSPO ligands in MCI, further research is needed as
well. This is due to some studies showing striking patterns of
TABLE 4 (Continued)
Study TSPO tracer Study population Main findings
Parbo et al. (2018) [11C]PK11195 6 AD patients,
20 MCI patients,
20 healthy
controls
In frontal, posterior cingulate, parahippocampal, lateral and posterior temporal
cortex, precuneus, and hippocampus, increased TSPO binding was found in
MCI patients compared to controls. In a mixed group of 16 MCI and AD
patients with high Aβ, microglial activation was correlated with PiB amyloid
uptake in frontal, parietal, and lateral temporal areas.
Fan, Okello, Brooks,
and Edison (2015)
[11C]PK11195 8 AD patients,
14 healthy
controls
AD patients demonstrated increased microglial tracer uptake in frontal, parietal,
occipital, temporal cortical areas, in addition to the striatum and hippocampus
relative to controls. Regionally distributed uptake on [11C]PK11195 was
correlated positively with amyloid binding on [11C]PiB, and negatively
correlated with brain glucose metabolism on FDG PET.
Parbo et al. (2017) [11C]PK11195 42 MCI patients,
10 healthy
controls
In amyloid positive MCI subjects, TSPO binding was elevated in frontal, parietal,
and lateral temporal regions compared to controls. Moreover, for this group, a
positive correlation on binding outcome was shown between [11C]PK11195
and [11C]PiB in frontal, temporal, and parietal brain areas.
Dani et al. (2018) [11C]PBR28 16 AD patients,
16 MCI patients,
19 healthy
controls
In AD and MCI patients, brain region-based clusters of positive correlations
were found between neuroinflammation on [11C]PBR28 and amyloid
retention on [18F]flutemetamol. A positive relationship also existed between
TSPO binding and tau aggregation measured by [18F]AV-1451.
Abbreviations: AD, Alzheimer's disease; aMCI, amnestic mild cognitive impairment; FDG, [18F]fludeoxyglucose; MCI, mild cognitive impairment; MRI,
magnetic resonance imaging; PET, positron emission tomography; TSPO, translocator protein.
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upregulated cortical tracer retention when compared to healthy con-
trols, especially in the temporal lobe (Fan et al., 2018; Yasuno et al.,
2012), and others showing no such significant differences (Knezevic
et al., 2017; Kreisl et al., 2013).
It is imperative to acknowledge the primary limitation of these
second-generation tracers, which is their particular sensitivity to a sin-
gle nucleotide polymorphism (SNP) of the TSPO gene. Genetic varia-
tion in the SNP rs6917 results in different patterns of binding affinity
to TSPO: high affinity binders, low affinity binders, and mixed affinity
binders. Therefore, it is essential to test for these genetic polymor-
phisms when examining data from these tracers and exclude low
affinity binders, which consist of approximately 10% of the popula-
tion, from analyses (Edison & Brooks, 2018; Yoder et al., 2013). Not
being influenced by this TSPO polymorphism can be considered an
advantage of [11C]PK11195.
5 | INTERPLAYS BETWEEN TAU, AMYLOID,
AND MICROGLIA
Overall, tau, amyloid, and TSPO radiotracers show good ability in the
detection of AD and MCI, in addition to associated neuropathology
(Table 5). However, the role of prolonged microglial activation in the
initiation and exacerbation of amyloid and tau neuropathology in AD
remains contested. Pro-inflammatory cytokines, which are produced
by microglia in response to neuronal damage (Smith, Das, Ray, &
Banik, 2012), experience a chronic activation due to Aβ exposure. This
leads to cellular neurotoxicity and potentially to clinical deterioration
in AD (Serrano-Pozo, Betensky, Frosch, & Hyman, 2016). These cyto-
kines have also been implicated in the manifestation of tau in its path-
ological state, specifically in tau hyperphosphorylation and NFT
generation (Maphis et al., 2015). Parbo et al. posit a model where
amyloid pathology precedes and activates microglia. Resultant cyto-
kines can then lead to the promotion of tau pathology (Parbo et al.,
2018). In support of this, PET imaging with both [11C]PK11195 and
second-generation TSPO ligands have shown positive correlations
between regional TSPO binding and amyloid load in AD and MCI
(Dani et al., 2018; Fan, Aman, et al., 2015; Fan, Okello, et al., 2015;
Hamelin et al., 2016; Knezevic et al., 2017; Parbo et al., 2017; Parbo
et al., 2018). Whilst older and using smaller samples, studies indicating
negative or no association between microglial activation and Aβ accu-
mulation (Kreisl et al., 2013; Okello, Edison, et al., 2009; Wiley et al.,
2009; Yokokura et al., 2011) highlights the need for future research to
clarify the nature of this relationship using in vivo brain imaging
technology.
Two very recent studies have sought to investigate whether asso-
ciations also exist between TSPO binding and both tau retention on
[18F]AV-1451 and amyloid load. The first found no association
between the two, but used a sample of patients primarily with prodro-
mal disease (Parbo et al., 2018). The second study evidenced a posi-
tive relationship between neuroinflammation and both tau and
amyloid pathology in patients with AD and MCI, with similar targeted
clusters of cortical regions (Dani et al., 2018). Furthermore, the corre-
lation between tau and neuroinflammation was demonstrated even in
participants without significant amyloid burden, suggesting a process
independent of Aβ. These results offer the first in vivo evidence in AD
and MCI patients that neuroinflammation and tau pathology have a
pathophysiological link.
6 | CONCLUSIONS
Molecular imaging with PET has shed light into the complex interplay
between Aβ, tau, and neuroinflammation in AD and MCI and helped
to clarify to what extent these are part of the normal ageing process
or if they represent a distinct pathophysiological process. It has also
assessed the patterns of neuropathological regional depositions and
their relation to cognitive decline, disease progression and, ultimately,
neurodegeneration.
In vivo imaging of dementia-related pathology through the
reviewed PET radioligands has several benefits. First, a preclinical
detection of the disease can be achieved by examining early molecular
changes. In addition, the differential diagnosis process between AD
and other neurodegenerative disorders can be refined through a focus
on characteristic neuropathological mechanisms. From a research per-
spective, these techniques allow for the study of relationships
TABLE 5 Studies examining sensitivity and specificity (in %) of amyloid, tau, and TSPO tracers in the detection of AD and neuropathology
Tracer
target Tracers Studies
Discriminating AD from
healthy controls
Detecting AD-related
neuropathology
Amyloid [11C]PiB
[18F]florbetapir
[18F]flutemetamol
[18F]florbetaben
Rowe et al. (2010), Clark et al. (2012), Camus
et al. (2012), Hatashita et al. (2014), Barthel
et al. (2011), Rowe et al. (2008), Villemagne
et al. (2011), Tiepolt et al. (2013),
Vandenberghe et al. (2010), Sabri et al.
(2015), Ikonomovic et al. (2016)
Sensitivity: 80–100%
Specificity: 66–96%
Sensitivity: 91–97.9%
Specificity: 90–100%
Tau [18F]AV-1451
[18F]THK5351
Chen et al. (2018),
Wang et al. (2016),
Maass et al. (2017)
Sensitivity: 78.8–100%
Specificity: 45–95%
Not available
TSPO [11C]PK11195 Cagnin et al. (2001) Sensitivity: 75% Not available
Abbreviations: AD, Alzheimer's disease; TSPO, translocator protein.
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between cognition and specific neurodegenerative processes across
the AD continuum. Finally, these PET molecular targets can serve as
surrogate markers for treatment efficacy and may represent potential
means of therapeutic intervention.
This review has demonstrated promising results regarding the role
of PET molecular imaging in the diagnosis of AD and MCI and their
underlying pathological processes, supporting its use as a research
tool and an adjunct in clinical practice. Also highlighted are a number
of areas of uncertainty and various tracers' limitations. The interplay
between amyloid, tau, and neuroinflammation is an exciting new area
of investigation that has only recently become possible through the
development of an expanded repertoire of PET tracers. Given the pro-
posal that the role of neuroinflammation in AD pathogenesis changes
over the disease course, future multitracer longitudinal studies are
required.
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